MONDAY, AUGUST 17

**Keynote Address**

**James P. Allison**, University of Texas MD Anderson Cancer Center, USA

*Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms*

**Mechanisms of Action I**

*Ira Mellman*, Genentech, Inc., USA

*Mechanistic Basis of Cancer Immunotherapy*

*Kelli Connolly*, Yale University, USA

*Short Talk: Tumor-Draining Lymph Nodes Contain an Untapped Reservoir of Stem-Like CD8 T Cells*

**AHyun Choi**, Novartis Institutes for BioMedical Research, USA

*Short Talk: Loss of EMC Inhibits Tumor Growth through Enhanced Adaptive Immune Response*

**Mechanisms of Action II**

**Jane Oliaro**, Peter MacCallum Cancer Centre, Australia

*Identifying New Targets for Cancer Immunotherapy*

**Vandana Kalia**, University of Washington and Seattle Children’s Research Institute, USA

*Short Talk: PD-1 Signals Are Critical for Maintenance of CD8 T Cell Memory*

**Katie Campbell**, University of California, Los Angeles, USA

*Short Talk: Integrating DNA and RNA Sequencing Analysis to Describe Somatic Alterations and Expression in the HLA Gene Loci*

**Stephen Mok**, MD Anderson Cancer Center, USA

*Short Talk: Late Interferon-Gamma Blockade Improves Antitumor Efficacy of Anti-CTLA-4 and Anti-PD-1 Combination Treatment*

**Mechanisms of Response I**

**Siwen Hu-Lieskovsk**, Huntsman Cancer Institute, USA

*Clinical Testing Strategies against Heterogenous Mechanisms of Immune Resistance*

**Antoni Ribas**, University of California, Los Angeles, USA

*Mechanisms of Primary and Acquired Resistance to PD-1 Blockade Therapy*

**Chang Liu**, University of Pittsburgh, USA

*Short Talk: Neuropilin-1 Is a T Cell Memory Checkpoint Limiting Long-Term Anti-Tumor Immunity*

**Mechanisms of Response II**

**Padmanee Sharma**, University of Texas MD Anderson Cancer Center, USA

*From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy*

*Yuxuan Miao*, Rockefeller University, USA

*Short Talk: Adaptive Immune Resistance Emerges From Tumor-Initiating Stem Cells*

**Shira Tabachnick-Cherny**, University of Washington, USA

*Short Talk: Characterization of Myeloid Cells Subsets in the Tumor Microenvironment of Merkel Cell Carcinoma*

**Zoila Areli Lopez Bujanda**, Johns Hopkins University, USA

*Short Talk: ADT-Mediated Intra-Tumoral Myeloid Infiltration Promotes Resistance to Immune Checkpoint Blockade in Prostate Cancer*

**Poster Session**

**TUESDAY, AUGUST 18**

**Therapeutic Play I**

**Yvonne Y. Chen**, University of California, Los Angeles, USA

*Engineering Next-Generation CAR-T Cell Therapy for Cancer*

*Juan C. Jaen*, Arcus Biosciences, Inc., USA

*Clinical Applications of Adenosine Pathway Inhibitors*

**Coralie Backlund**, Massachusetts Institute of Technology, USA

*Short Talk: Cell Penetrating Peptides Improve T Cell Response to Neoantigen Peptide Vaccines*

**Maija Hollmén**, University of Turku, Finland

*Short Talk: Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumours*

**Yingxiao Wang**, University of California, San Diego, USA

*Short Talk: Engineering Remotely Controllable CAR T Cells for Cancer Immunotherapy*

**Therapeutic Play II**

*Evan Scott*, Northwestern University, USA

*Engineered Nanobiomaterials for Cancer Immunotherapy*

**E. John Wherry**, University of Pennsylvania, USA

*Epigenetic Features of Exhausted Antitumor T Cells*

**Buvana Ravishankar**, Rapt Therapeutics, Inc., USA

*Short Talk: Targeting the Stress Response Kinase GCN2 Potentiates Anti-Tumor Immune Response*

**Anthony K. Park**, City of Hope, USA

*Short Talk: Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors*

**Patrick A. Ott**, Dana-Farber Cancer Institute, USA

*Short Talk: Personal Neoantigen Vaccines Induce Long-term Immune Responses in Patients with High Risk Melanoma*

**Meet-the-Editors Roundtable**

**Alessandra Fornarelli**, Frontiers, Switzerland

**Paloma Portela Torres**, SAGE Publications Ltd, UK

**Lise Roth**, European Molecular Biology Organization, Germany

**Genomics of Cancer I**

*Priti Hegde*, Foundation Medicine, USA

*Pan-Cancer Analysis of Allele-Specific HLA-I Loss Suggests Widespread Occurrence across a Diverse Range of Tumor Types*

**Eliezer M. Van Allen**, Dana-Farber Cancer Institute, USA

*Tumor Genomics and Selective Response to Cancer Immunotherapy*
**Nadine A. Defranoux**, Parker Institute for Cancer Immunotherapy, USA  
**Short Talk:** Strategies to Improve the Sensitivity and Ranking Ability of Neoantigen Prediction Methods: Report on the Results of the Tumor nEOantigen SeLection Alliance (TESLA)

**Gloria Bora Kim**, University of Pennsylvania, USA  
**Short Talk:** Splice Variants as Neoantigens for Cancer Immunotherapy

**Genomics of Cancer II**

**Elaine R. Mardis**, Nationwide Children's Hospital, USA  
**Immunogenomics and the TME in Pediatric CNS Cancers**

**Thomas D. Wu**, Genentech, Inc., USA  
**Short Talk:** Peripheral T Cell Expansion Predicts Tumor Infiltration and Clinical Response to Cancer Immunotherapy

**Debattama Sen**, Harvard Medical School, USA  
**Short Talk:** Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control

**WEDNESDAY, AUGUST 19**

**Single Cell I**

**James R. Heath**, Institute for Systems Biology, USA  
**Single Cell Approaches to Analyzing Antitumor Responses**

* **Ansuman Satpathy**, Stanford University School of Medicine, USA  
**Single-Cell Genomics in Cancer Immunotherapy**

**Christine Carine Mousson**, Genentech, Inc., USA  
**Short Talk:** Local Heterogeneity of Response to CIT: Learning from the STAMP Live Imaging Model

**James C. Lee**, University of California, San Francisco, USA  
**Short Talk:** Liver Metastasis Mediated Control of Systemic Tumor-Specific Immunity and Response to Checkpoint Immunotherapy

**Single Cell II**

* **Sohail F. Tavazoie**, Rockefeller University, USA  
**Depleting Myeloid-Suppressive Cells for Cancer Immunotherapy**

**Theodore Roth**, University of California, San Francisco, USA  
**Short Talk:** Parallel Engineering of Immune Cell Genomes by Pooled Knockin Targeting

**Amanda Oliver**, Peter MacCallum Cancer Centre, Australia  
**Short Talk:** Tissue-Specific Tumour Microenvironments Influence Responses to Immunotherapy

---

* Session Chair † Invited but not yet accepted  
Program current as of August 31, 2020. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit [https://www.keystonesymposia.org](https://www.keystonesymposia.org).